Explore

Vox Vox
The strange reason flu shots have been so hard to improve

The strange reason flu shots have been so hard to improve

America finally has an mRNA flu shot. Now comes the fight to actually use it.
Rapid Read Rapid Read
FDA-Approved Synthetic THC Shows Promise in Reducing PTSD Nightmares

FDA-Approved Synthetic THC Shows Promise in Reducing PTSD Nightmares

A recent study published in Nature Medicine reveals that dronabinol, a synthetic THC medication approved by the U.S. Food and Drug Administration, has shown effectiveness in reducing the frequency and intensity of nightmares in patients with post-traumatic stress disorder (PTSD). Conducted by German researchers, the study involved a randomized controlled trial with 171 adults, where participants received either dronabinol or a placebo over a 10-week period. Results indicated that 57.9% of those on dronabinol experienced a significant reduction in nightmares, compared to 29% on placebo. The study highlights the potential of dronabinol as a treatment option for PTSD-related nightmares, although it did not show improvements in overall PTSD severity or related depression.
Trendline Trendline
INmune Bio Advances Ebstracel for RDEB with UK Regulatory Alignment

INmune Bio Advances Ebstracel for RDEB with UK Regulatory Alignment

INmune Bio Advances Ebstracel for RDEB with UK Regulatory Alignment
Rapid Read Rapid Read
FDA Approves Moderna's mRNA Flu Vaccine mFlusiva for Adults 50 and Older

FDA Approves Moderna's mRNA Flu Vaccine mFlusiva for Adults 50 and Older

The U.S. Food and Drug Administration (FDA) has approved Moderna's mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older. This approval marks a significant advancement in influenza vaccine development, leveraging mRNA technology to potentially shorten production times compared to traditional vaccines. The vaccine has received full approval for individuals aged 50 to 64, while those aged 65 and older have been granted accelerated approval, pending further clinical trials. The decision follows positive results from late-stage clinical trials involving over 40,000 participants across 11 countries, demonstrating mFlusiva's efficacy. The vaccine is expected to be available for the upcoming flu season, although its distribution may be impacted by the lack of a formal recommendation from the CDC's Advisory Committee on Immunization Practices (ACIP).
Rapid Read Rapid Read
Walmart Recalls Pistachio Nut Butter Due to Salmonella Risk in Multiple States

Walmart Recalls Pistachio Nut Butter Due to Salmonella Risk in Multiple States

Walmart has issued a recall for a batch of Bettergoods Pistachio Nut Butter due to potential Salmonella contamination. The recall affects 6.7-ounce glass jars with lot number LB028ACP04, a best-by date of January 28, 2027, and UPC 194346207961. The U.S. Food and Drug Administration detected the bacteria during routine testing at a Walmart store in Florida. The recall impacts 19 states, including Tennessee and Georgia. Consumers are advised to stop consuming the product and return it to any Walmart store for a full refund. No illnesses have been reported in connection with the recall.
Rapid Read Rapid Read
US Approves First mRNA Flu Vaccine Amidst Research Funding Shift

US Approves First mRNA Flu Vaccine Amidst Research Funding Shift

The United States has approved its first mRNA-based flu vaccine, mFLUSIVA, developed by Moderna. This approval by the Food and Drug Administration (FDA) is a milestone in modernizing flu vaccine development. The vaccine is targeted at adults aged 50 and older and is expected to be available for the 2026-2027 flu season. The approval comes a year after the Department of Health and Human Services (HHS) ceased funding for mRNA vaccine research, citing a shift towards alternative solutions. Despite this, the vaccine's approval is seen as a significant step forward in public health.
Rapid Read Rapid Read
FDA Approves Moderna's mRNA Flu Vaccine for Older Adults, Offering New Protection

FDA Approves Moderna's mRNA Flu Vaccine for Older Adults, Offering New Protection

The Food and Drug Administration (FDA) has approved Moderna's mRNA-based flu vaccine, mFlusiva, marking a significant advancement in flu prevention for adults aged 50 and older. This approval is the first of its kind for a non-COVID-related mRNA vaccine in the United States. The vaccine is initially approved for individuals aged 50 to 64, with further studies planned for those over 65. Clinical trials demonstrated that mFlusiva is 26.6% more effective than traditional flu vaccines. Moderna plans to make the vaccine available at select retailers soon, as other flu vaccines are already arriving in pharmacies for the upcoming vaccination season.
Trendline Trendline
GRAIL's Galleri Test Shows Promise in Early Cancer Detection

GRAIL's Galleri Test Shows Promise in Early Cancer Detection

GRAIL's Galleri Test Shows Promise in Early Cancer Detection
Rapid Read Rapid Read
FDA Nears Decision on First mRNA Flu Vaccine Approval

FDA Nears Decision on First mRNA Flu Vaccine Approval

The U.S. Food and Drug Administration (FDA) is on the verge of deciding whether to approve the first flu vaccine utilizing mRNA technology, similar to that used in COVID-19 vaccines. This decision comes amid ongoing debates about the safety and efficacy of mRNA vaccines, with Health Secretary Robert F. Kennedy Jr. expressing skepticism about the technology. The approval of an mRNA flu vaccine could mark a significant advancement in vaccine development, offering a new tool in the fight against influenza.
Trendline Trendline
GRAIL Reports Financial Growth and Advances in Cancer Detection Technology

GRAIL Reports Financial Growth and Advances in Cancer Detection Technology

GRAIL Reports Financial Growth and Advances in Cancer Detection Technology
Rapid Read Rapid Read
FDA Approves First mRNA-Based Flu Vaccine by Moderna for Adults Over 50

FDA Approves First mRNA-Based Flu Vaccine by Moderna for Adults Over 50

The U.S. Food and Drug Administration (FDA) has approved the first mRNA-based flu vaccine, mFLUSIVA, developed by Moderna, for adults aged 50 and older. This approval is a significant milestone in the use of mRNA technology beyond COVID-19 vaccines. The vaccine was found to be 27% more effective than standard flu shots in clinical trials involving over 40,000 participants. The mRNA platform allows for quicker production and potentially better matching of vaccines to circulating flu strains. Despite initial hesitance from the FDA and the Department of Health and Human Services, the vaccine's approval reflects its potential to address public health challenges.
Rapid Read Rapid Read
FDA Approves Moderna's mRNA Flu Vaccine for Adults Over 50, Reversing Previous Decision

FDA Approves Moderna's mRNA Flu Vaccine for Adults Over 50, Reversing Previous Decision

The U.S. Food and Drug Administration (FDA) has approved Moderna's mRNA-based flu vaccine for individuals aged 50 and older, marking a significant reversal from an earlier decision not to review the shot. This approval is based on data from a late-stage trial involving over 40,000 adults, which demonstrated that the vaccine was 26.6% more effective than existing standard-dose flu vaccines. The approval paves the way for the vaccine to be available in the U.S. next year, although it does not impact the ongoing Health Canada review of the same vaccine. Health experts have noted the potential for mRNA vaccines to offer higher effectiveness and shorter manufacturing timelines compared to traditional flu vaccines, which are grown in chicken eggs and rely on predictions of flu strains months in advance.